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Dear Editor,
Opportunities exist for cross-specialty learning between dermatology and other medical
disciplines; to the benefit of patients, clinical decision making and professional
development. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) promotes the concept of ‘psoriatic disease’ to encompass psoriasis and psoriatic
arthritis, and in their new disease management recommendations emphasise the
importance of collaborative working between dermatologists and rheumatologists1. Whilst
the group primarily focuses on adult disease we suggest that a similar model should exist for
the paediatric population.
Juvenile psoriatic arthritis (JPsA) is a separate disease to psoriatic arthritis in adults and is a
distinct subset of juvenile idiopathic arthritis (JIA); an inflammatory arthritis with onset
under the age of 16 years and unknown aetiology2. Diagnosis of cutaneous psoriasis and
psoriatic nail disease are both core components of the diagnostic classification for JPsA3.
However, recognition of psoriasis in children can be more challenging compared to adult
disease as the signs are often more subtle4.
Local experience in our Nottingham combined paediatric dermatology and rheumatology
clinics has demonstrated the shared benefit of cross-speciality learning for the assessment
and management of JPsA.
To identify learning opportunities we conducted structured telephone interviews with UK
paediatric rheumatologists. The interviews aimed to ascertain paediatric rheumatologists’
current practice for assessing for psoriasis, the impact a diagnosis of JPsA has on the
management of arthritis, experience of the presentation of skin and joint disease, and
recommendations on improving the detection of JPsA.
In the UK paediatric rheumatology is a specialist commissioned service with 12 designated
centres; a rheumatologist at each centre was identified through the British Society of
Paediatrics and Adolescent Rheumatology (BSPAR). Rheumatologists were contacted and
provided study information by email, verbally consented for audio recording and undertook
the interviews as part of service evaluation.
The interviews were conducted by one interviewer (EBT) following an interview guide of
open and closed questions and transcribed as intelligent verbatim. Categorical responses
were analysed quantitatively as percentages and Framework Analysis was used to identify
common themes in open responses5.
Ten out of 12 (83%) centres of paediatric rheumatology expertise were interviewed based in
England, Scotland and Northern Ireland; a moderate sample that are likely to be
representative of current paediatric rheumatology practice. All clinicians had children with
inflammatory arthritis under their care.
Table 1 presents the results of questions about the assessment for psoriasis and the impact
a diagnosis of JPsA has on the management of arthritis. Hidden site psoriasis was defined as
psoriasis occurring behind the ears or in the umbilicus, flexures, groin, genitals and natal
cleft. Only 50% of rheumatologists ask about or examine at least one hidden site, and a
smaller number examine the groin (20%), genitals (10%) and natal cleft (10%). However,
paediatric rheumatologists rated their confidence in assessing for psoriasis on average at 6.4
(0= no confidence at all, 10 =very confident).
The three most frequent suggestions to improve rheumatologists’ recognition of psoriasis
were a close working relationship with dermatologists, experiential training and a diagnostic
tool. The majority of rheumatologists felt a diagnosis of JPsA compared to other JIA
subtypes made an impact on the explanation given to patients/families (70%), the
treatment plan (80%) and long-term outcomes (70%); highlighting the likely chronic and
aggressive course of JPsA.
Eight rheumatologists (80%) found it difficult to estimate the percentage of patients
presenting with skin, joint or simultaneous disease. Nine rheumatologists (90%)
recommended that paediatric dermatologists could use the Paediatric Gait Arms Legs Spine
(pGALS) tool to screen children with psoriasis for JPsA and a third (30%) commented that it
is important to practise the technique6.
Opportunities exist for paediatric dermatologists and rheumatologists to learn from each
other. JPsA may be missed by paediatric rheumatologists if psoriasis occurring in hidden
sites are not asked about and examined. It is important to examine these sites as there is
sometimes discordance between patients’ awareness of psoriasis and changes detected on
examination. Future work could further explore dermatological practice amongst
rheumatologists, including recognition of nail disease and disease severity. Dermatologists
are best placed to develop paediatric psoriasis training material and diagnostic guidance for
their rheumatology colleagues.
Currently there is no specific guidance on how children with psoriasis should be screened
for JPsA. Available screening tools for adult psoriatic arthritis have not been validated for
use in children7. Paediatric rheumatologists are likewise best placed to develop screening
recommendations and related training for JPsA assessment by dermatologists. From these
interviews pGALS should be considered as an annual screening tool for use in paediatric
dermatology clinics.
We conclude that these interviews provide clear examples of the need for paediatric
dermatologists and rheumatologists to learn from each other. Working groups, consensus
work and research studies are needed to take forward these strategies to improve the
detection of JPsA. At a time of limited healthcare resources, this work should open
discussions about electronic multi-disciplinary working and teaching material.
Acknowledgements
We would like to acknowledge the following rheumatologists who supported this study by
participating in the interviews.
K. Bailey, Department of Paediatric Rheumatology, Nuffield Orthopaedic Centre, Oxford,
OX3 &HE, UK
D. Hawley, Department of Paediatric Rheumatology, Sheffield Children's NHS Foundation
Trust, Sheffield, S10 2TH, UK
L. McCann, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation
Trust , West Derby, Liverpool, L12 2AP, UK
J. McDonagh, Department of Paediatric Rheumatology, Birmingham Children’s Hospital NHS
foundation Trust, Birmingham, B4 6NH, UK
K. Warrior, Department of Paediatric Rheumatology, Nottingham Children’s Hospital,
Nottingham, NG7 2UH, UK
M. Wood, Department of Paediatric Rheumatology, Leeds General Infirmary, Leeds, LS1 3EX,
UK
References
1 Coates LC, Murphy R, Helliwell PS. New GRAPPA recommendations for the
management of psoriasis and psoriatic arthritis: process, challenges and
implementation. The British journal of dermatology 2016; 174: 1174-8.
2 Cassidy JT PR, Laxer RM, Lindsley CB. Juvenile Psoriatic Arthritis. In: Textbook of
Paediatric Rheumatology (Cassidy JT, ed), 6th edn. Canada: Saunders Elsevier.
2011; 287-97.
3 Petty RE, Southwood TR, Manners P et al. International League of Associations for
Rheumatology classification of juvenile idiopathic arthritis: second revision,
Edmonton, 2001. The Journal of rheumatology 2004; 31: 390-2.
4 Kapila S, Hong E, Fischer G. A comparative study of childhood psoriasis and
atopic dermatitis and greater understanding of the overlapping condition,
psoriasis-dermatitis. The Australasian journal of dermatology 2012; 53: 98-105.
5 Gale NK, Heath G, Cameron E et al. Using the framework method for the analysis
of qualitative data in multi-disciplinary health research. BMC medical research
methodology 2013; 13: 117.
6 Foster HE, Jandial S. pGALS - paediatric Gait Arms Legs and Spine: a simple
examination of the musculoskeletal system. Pediatric rheumatology online journal
2013; 11: 44.
7 Coates LC, Aslam T, Al Balushi F et al. Comparison of three screening tools to
detect psoriatic arthritis in patients with psoriasis (CONTEST study). The British
journal of dermatology 2013; 168: 802-7.
Structured Question Number of respondents = n (%)
When assessing children with
inflammatory arthritis, do you
routinely ask any questions
about skin disorders?
Yes - 10/10 (100%)
Directly ask about psoriasis – 7/10 (70%)
When assessing children with
inflammatory arthritis, are there
any specific areas of the body
where you ask about changes to
the skin?
Scalp – 7/10 (70%), behind the ears – 1/10 (10%), face – 0/10 (0%), trunk – 0/10 (0%), umbilicus – 3/10 (30%), limbs – 3/10 (30%), acral –
0/10 (0%), nails – 4/10 (40%), flexures – 0/10 (0%), groin – 2/10 (20%), genitals – 0/10 (0%), natal cleft – 3/10 (30%).
Hidden sites* asked about – 3/10 (30%)
When assessing children with
inflammatory arthritis, are there
any specific areas of the body
where you examine for skin
changes?
Scalp – 9/10 (90%), behind the ears – 3/10 (30%), face – 2/10 (20%), trunk – 3/10 (30%), umbilicus – 3/10 (30%), limbs – 5/10 (50%), acral
1/10 (10%), nails – 5/10 (50%), flexures – 2/10 (20%), groin – 2/10 (20%), genitals – 1/10 (10%), natal cleft – 1/10 (10%)
Hidden sites* examined – 5/10 (50%)
How confident do you feel about
diagnosing psoriasis on a scale of
1 to 10, 1 being not at all
confident to 10 being very
confident?
4 – 1/10 (10%), 5 – 2/10 (20%), 7 – 6/10 (60%), 8 – 1/10 (10%)
Mean average score – 6.4
In your experience, are there any
reasons why making a diagnosis
of psoriasis can be difficult?
Example quotations provided.
Atypical appearance –
8/10 (80%)
“appearance is not
characteristic”
“not very scaly in the
scalp…difficult if the GP
has already started
treatment. You aren’t
seeing the true clinical
picture”
Anatomical area of the
body involved – 5/10
(50%)
“young children
especially nappies and
other excoriated areas”
“palmar plantar
involvement”
Minimal amounts of skin
disease – 6/10 (60%)
“small areas, can vary
from time to time”
“when the presentation is
mild sometimes the family
can dismiss or not notice
the changes…a small patch
in the scalp may be missed
without a very thorough
scalp examination”
Similarity in appearance
to other skin disease –
5/10 (50%)
“with the nails fungal
needs to be excluded:
“rashes can be difficult
to diagnose to a non-
dermatologist, can
appear very similar”
No family history –
2/10 (20%)
“no family history of
psoriasis”
Can you make any suggestions
about what would help you
diagnose psoriasis and therefore
psoriatic arthritis? Example
quotations provided.
Diagnostic test – 1/10
(10%)
“any imaging ….skin
ultrasound”
Diagnostic criteria –
3/10 (30%)
“a list of criteria for
diagnosing psoriasis”
Experiential
training/clinical education
– 4/10 (40%)
“active learning from
colleagues… courses…
clinical experience“
Close working
relationship between
rheumatology and
dermatology – 6/10
(60%)
“we have a combined
clinic monthly”
“review by a
dermatologist who has
experience around
children and
understands the
importance around
making an accurate
diagnosis”
Not a problem that
needs to be
addressed – 1/10
(10%)
“not a big problem”
From your expertise, do you
consider there to be a difference
between juvenile idiopathic
arthritis and juvenile psoriatic
arthritis?
Yes – 8/10 (80%)
No – 2/10 (20%)
Specific rheumatological features in JPsA– 7/10 (70%) which include: dactylitis 5/10 (50%), enthesitis – 1/10 (10%), small joints of the
hand/DIP -4/10 (40%), minimal swelling/drier synovitis/subtle -3/10 (30%), more aggressive -1/10 (10%), systemic inflammation – 1/10
(10%)
Each subtype is a different disease – 1/10 (10%)
In your experience do you feel
there are any particular joint
patterns in children with
psoriatic arthritis?
Small joints of the hand/DIP(60%), large joints (50%), dactylitis (40%), oligoarthritis/asymmetric (40%), mid/hindfoot (30%), sacroilitis
(20%), polyarticular (20%), minimal swelling (10%) and no clear pattern (10%).
Does a diagnosis of juvenile
psoriatic arthritis instead of
juvenile idiopathic arthritis
influence what you explain to
children and their parents?
Example quotations provided.
Yes – 7/10 (70%) No – 3/10 (30%)
Helps disease
explanation (skin and
joints) – 2/10 (20%)
Comorbidities – 2/10
(20%)
“need to monitor eyes
Cautious explanation of
genetics - 2/10 (20%)
“try to stay away from the
Persistent disease and
risk of joint damage –
6/10 (60%)
Treatment strategy –
4/10 (40%)
“early intervention
Table 1: Responses to questions about how paediatric rheumatologists assess children with
inflammatory arthritis for psoriasis and the impact a diagnosis of juvenile psoriatic arthritis
has on their management of arthritis. *Hidden psoriasis refers to psoriasis behind the ears,
umbilicus, flexures, groin, genitals and natal cleft.
“starting point for
explaining autoimmune
disease …helps explain
treatment as you can
use methotrexate for
skin and joints”
for uveitis” blame of genetics” “prolonged …. can be
more damaging”
“less reassuring
regarding spontaneous
remission”
can be very effective…
slightly different
approach”
“intermittent lifelong
immunosuppression”
Does a diagnosis of juvenile
psoriatic arthritis instead of
juvenile idiopathic arthritis
influence your treatment plan?
Example quotations provided.
Yes – 8/10 (80%) No – 2/10 (20%)
Lowers the threshold for treatment escalation 5/10
(50%)
“lower threshold for starting a DMARD,
methotrexate in patients with involvement of less
than 5 joints”
“inclined to start systemic earlier… lower threshold to
escalate treatment”
Choice of biologic therapy – 2/10 (20%)
“more likes to choose Humira over
Enbrel”
Combined approach for skin/uveitis
and joints – 2/10 (20%)
“if uveitis and skin involvement
may alter treatment used”
In your experience, are long-term
outcomes different in children
with psoriatic arthritis compared
to juvenile idiopathic arthritis?
Example quotations provided.
Yes – 7/10 (70%) No – 3/10 (30%)
Persistent disease – 5/10 (50%)
“can have ongoing disease into adulthood”
“less likely to go into remission”
Risk of long-term joint damage and
comorbidity – 4/10 (40%)
“adults have been found to have damage
from undertreated psoriatic JIA”
“appears to be more aggressive and
erosive but we don’t have that
information yet”
Increased need for aggressive
treatment – 2/10 (20%)
“tend to start methotrexate and
biologic earlier in these patients”
